Clinical Trial Update: Syndecan 1 as Biomarker for Inflammation

View source ↗

Summary

A clinical trial update notes investigation of Syndecan 1 as a biomarker for inflammation in colitis, with no trial status reported.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colitis

Snippet

Sponsor: Helios Albert-Schweitzer-Klinik Northeim | Conditions: Colitis | Status: UNKNOWN